Comments

Iterum Therapeutics Analyst Ratings

ITRMNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$0.4014

0.01233.17%

Last update: Dec 18, 9:48 AM

Overview News Earnings

Analyst Ratings

Insider Trades Short Interest Stock Report

Consensus Rating¹

Buy

Highest Price Target¹

$9.00

Lowest Price Target¹

$5.00

Consensus Price Target¹

$7.00

Iterum Therapeutics Analyst Ratings and Price Targets | NASDAQ:ITRM | Benzinga

Iterum Therapeutics PLC has a consensus price target of $7 based on the ratings of 2 analysts. The high is $9 issued by HC Wainwright & Co. on May 8, 2025. The low is $5 issued by HC Wainwright & Co. on September 10, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 8, 2025, September 10, 2024, and August 15, 2024, respectively. With an average price target of $6.33 between HC Wainwright & Co., there's an implied 1500.13% upside for Iterum Therapeutics PLC from these most-recent analyst ratings.

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

HC Wainwright & Co.

¹calculated from analyst ratings

Analyst Ratings for Iterum Therapeutics

					Get Alert
May 8, 2025	2173.88%	Joseph PantginisHC Wainwright & Co. 59%	9	Previous Current Buy	Get Alert
Sep 10, 2024	1163.26%	Ed ArceHC Wainwright & Co. 72%	5 5	Previous Buy Current Buy	Get Alert
Aug 15, 2024	1163.26%	Ed ArceHC Wainwright & Co. 72%	5 6	Previous Buy Current Buy	Get Alert
Jun 21, 2024	1415.92%	Ed ArceHC Wainwright & Co. 72%	6 6	Previous Buy Current Buy	Get Alert
May 31, 2024	1415.92%	Ed ArceHC Wainwright & Co. 72%	6 6	Previous Buy Current Buy	Get Alert
May 14, 2024	1415.92%	Ed ArceHC Wainwright & Co. 72%	6 6	Previous Buy Current Buy	Get Alert
Apr 30, 2024	1415.92%	Ed ArceHC Wainwright & Co. 72%	6 6	Previous Buy Current Buy	Get Alert
Apr 1, 2024	1415.92%	Ed ArceHC Wainwright & Co. 72%	6 6	Previous Buy Current Buy	Get Alert
Mar 6, 2024	1415.92%	Ed ArceHC Wainwright & Co. 72%	6 6	Previous Buy Current Buy	Get Alert
Feb 7, 2024	1415.92%	Ed ArceHC Wainwright & Co. 72%	6 6	Previous Neutral Current Buy	Get Alert

FAQ

What is the target price for Iterum Therapeutics (ITRM) stock?

The latest price target for Iterum Therapeutics (NASDAQ:ITRM) was reported by HC Wainwright & Co. on May 8, 2025. The analyst firm set a price target for $9.00 expecting ITRM to rise to within 12 months (a possible 2141.87% upside). 1 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Iterum Therapeutics (ITRM)?

The latest analyst rating for Iterum Therapeutics (NASDAQ:ITRM) was provided by HC Wainwright & Co., and Iterum Therapeutics their buy rating.

When was the last upgrade for Iterum Therapeutics (ITRM)?

The last upgrade for Iterum Therapeutics PLC happened on February 7, 2024 when HC Wainwright & Co. raised their price target to $6. HC Wainwright & Co. previously had a neutral for Iterum Therapeutics PLC.

When was the last downgrade for Iterum Therapeutics (ITRM)?

There is no last downgrade for Iterum Therapeutics.

When is the next analyst rating going to be posted or updated for Iterum Therapeutics (ITRM)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iterum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iterum Therapeutics was filed on May 8, 2025 so you should expect the next rating to be made available sometime around May 8, 2026.

Is the Analyst Rating Iterum Therapeutics (ITRM) correct?

While ratings are subjective and will change, the latest Iterum Therapeutics (ITRM) rating was a with a price target of $0.00 to $9.00. The current price Iterum Therapeutics (ITRM) is trading at is $0.40, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.